The Efficacy and Safety of Repeat-dose Potenfill for Temporary Penile Enhancement
Launched by MEDY-TOX · Feb 11, 2019
Trial Information
Current as of August 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Male subjects aged above 19 and below 65. (20≤male≥65)
- • Subjects will sign an informed consent form
- Exclusion Criteria:
- • Prior treatment for penile enhancement (e.g. fat, dermal graft).
- • Allergic to hyalluronic acid.
About Medy Tox
Medytox is a leading biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutics, particularly in the fields of neurology and aesthetics. With a robust pipeline of products, Medytox specializes in botulinum toxin and other neurotoxin derivatives, aiming to enhance patient outcomes through advanced treatments. The company is committed to rigorous clinical trials and regulatory compliance, ensuring the safety and efficacy of its therapies while driving forward the science of biotechnology. Medytox's dedication to excellence and innovation positions it at the forefront of the global biopharmaceutical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials